DeVivo Appointed President, CEO of AngioDynamics

Joseph M. DeVivo has been appointed president and CEO of AngioDynamics. DeVivo recently made industry headlines when he stepped down from his position as president of Smith & Nephew Inc.’s orthopedic reconstruction division on Aug. 5. He takes over for Scott Solano, who was named interim CEO in June and will return to his former role as senior vice president and chief technology officer. DeVivo’s first official day will be Sept. 7.

“Joe has been our top choice since we began our search,” said AngioDynamics Chairman Vincent Bucci. “Smith & Nephew recently reported that its orthopedic business had the fastest growth rate of all its business segments again during its most recent quarter while continuing to drive share. We are thrilled to have recruited the architect of this growth.”

DeVivo joined London, England-headquartered Smith & Nephew in 2007, and led its $2 billion global orthopedics business to record growth through emerging market penetration in China, India and Russia, new product platform launches, strategy creation for the company’s Visionaire patient-matched technology platform and creation and implementation of the Verilast marketing campaign for hips and knees. DeVivo pioneered the concept of the laboratory tested 30-year wear claim for Verilast, which created record growth in the company’s knee business.

Before his tenure at Smith & Nephew, DeVivo served as CEO and President of RITA Medical Systems. Latham, N.Y.-based AngioDynamics acquired RITA in 2006. Prior to his role at RITA Medical Systems, DeVivo was president, chief operating officer and director of Computer Motion Inc. He also has served as vice president and general manager of a $350 million division of TYCO International’s health care business, U.S. Surgical/Davis and Geck Sutures.

“AngioDynamics is a company with many strengths, and I look forward to working with the team to tackle our challenges, maximize our opportunities and drive growth,” DeVivo said.

“Joe has the track record and leadership expertise to help AngioDynamics capitalize on the full potential of the NanoKnife System, drive the successful launch of new products, execute our acquisition strategy, propel the company’s international growth plans, enhance our competitive position and drive the company’s profitability and shareholder value,” Bucci continued.

“Given his prior leadership of RITA Medical Systems, Joe already possesses the background and experience in the fastest growing market for AngioDynamics, which is oncology. Joe is a proven and enormously talented executive, and we are proud to welcome him to our company.”